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ABSTRACT
The effect of allogeneic versus syngeneic killer cells derived from normal or severe combined immunodefi-
ciency disease (SCID) mice was evaluated for induction of antitumor reaction in a murine model of mammary
carcinoma. Tumor cells of H-2d origin were injected intravenously into H-2d/b mice 24 hours after total body
irradiation (4 Gy). On the following day, lymphokine-activated killer (LAK) splenocytes, derived from either
minor (H-2d) or major (H-2b) histocompatibility complex (MHC)–mismatched parental normal mice or MHC
(H-2b)–mismatched SCID mice, were given intravenously. LAK cells of H-2d normal or SCID mice, syngeneic
to the tumor, were inoculated in parallel. The results show that LAK cells derived from minor histocompat-
ibility complex–mismatched or MHC-mismatched parental normal mice improved the probability of tumor-
free survival as compared with LAK cells syngeneic to the tumor cells, but they aggravated the severity of
graft-versus-host disease. SCID splenocytes serving as a source of natural killer (NK) cells were expanded and
activated in vitro by rIL-2 to obtain a sufficient number of DX5 CD3 CD8 NK cells (SCID-LAK). H-2b
SCID-LAK cells did not cause graft-versus-host disease and significantly delayed tumor growth compared with
syngeneic H-2d SCID-LAK cells, as indicated by tumor colony assays in vitro and adoptive transfer experi-
ments. However, the graft-versus-tumor effect was not long lasting, and treated mice finally died of tumor. Our
results show an advantage of allogeneic over syngeneic cell therapy for achieving a graft-versus-tumor effect
by rIL-2–activated T cells and NK cells. Periodic repetition of NK treatments may be required to achieve more
durable antitumor effects.
© 2004 American Society for Blood and Marrow Transplantation
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gNTRODUCTION
Immunotherapy strategies that aim to amplify an
mmune response and break tolerance to the tumor
ells are mostly based on the use of tumor-syngeneic/
utologous effector cells in both experimental models
nd cancer patients [1-11]. During the last decade, an
ncreasing number of protocols based on an allogeneic
eaction between immunocompetent effector cells and
umor target cells were developed. This strategy
merged from clinical observations after allogeneic
ematopoietic stem cell transplantation (HSCT),
here there seemed to be a correlation between graft-
ersus-leukemia (GVL) effects and graft-versus-host c
0isease (GVHD) [12]. Furthermore, donor lympho-
yte infusion given after HSCT was shown to play a
ey role in eradicating malignant cells and preventing
elapse [3-6,13-15]. The antitumor effects of alloreac-
ive donor lymphocytes, designated as GVL and graft-
ersus-tumor (GVT) effects, were ascribed mainly to
llogeneic T lymphocytes that recognize malignant
ells in a major histocompatibility complex (MHC)–
estricted fashion and to MHC-nonrestricted natural
iller (NK) and lymphokine-activated killer (LAK)
ells [16-20]. Unlike T cells, which are activated
hrough recognition of foreign epitopes, it is sug-
ested that NK-cell activation is mediated via MHC
lass I missing-self epitopes when the negative signals
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Allogeneic Killer Cells for Cancer
Bf killing-inhibitory receptors (KIR) on the NK cells
annot be neutralized [21-23]. Allogeneic cell therapy
alloCT) has pronounced antitumor effects but is of-
en complicated by the development of GVHD, which
s ascribed to immunocompetent donor CD4 and
D8 T cells that target organs such as skin, gut,
iver, and lung [24-27]. In contrast to T cells, alloge-
eic NK cells can mediate antitumor responses with-
ut causing GVHD when administered to immuno-
ompromised mice or humans [17-20], thus
uggesting that NK alloreactivity warrants further
tudy as a potentially safer antitumor modality.
Encouraged by the efﬁcient antitumor effects of
lloCT in previous studies, yet aware of the associated
omplications, we compared the efﬁcacy of allogeneic
ersus syngeneic cell therapy (synCT) by using various
ources of lymphokine-activated T and NK cells in an
ttempt to induce GVT effects in a murine model of
ammary carcinoma.
ATERIALS AND METHODS
ice
BALB/c (H-2d) (BALB), C57BL/6 (H-2b) (C57)
BA/2 (H-2d) (BALB/cXC57BL/6) F1 (H-2
d/b) (F1),
nd C.B-17/IcrHsd-scid (H-2d; SCID, severe com-
ined immunodeﬁciency disease) (C.B-17) mice, aged
to 12 weeks, were obtained from Harlan Sprague
awley (Indianapolis, IN). C57BL/6J-Prkdcscid/
zJ (H-2b) (C57 SCID) mice were obtained from
ackson Laboratory (Bar Harbor, ME). All mice were
aintained in the Hadassah University Hospital in
ccordance with the national laws and regulations for
he protection of animal welfare.
umor Cells
4T1 is a tumor cell line established from a cell
ubpopulation isolated from a single spontaneously
rising mammary tumor in a BALB/c (H-2d) mouse
28]. 4T1 cells were maintained in 10% fetal bovine
erum, 2 mmol/L glutamine streptomycin 100 g/
L, penicillin 100 U/mL, and 1% nonessential amino
cid (culture medium of 4TI) and prepared for intra-
enous (IV; 0.25 mL per mouse) and intradermal (0.1
L per mouse) inoculation or were prepared for in
itro assays as described previously [29]. Yac-1 (H-2a)
Yac) is a cell line sensitive to the cytotoxic activity of
K cells [30] and acts as target cells in chromium 51
elease assays. Cells were kept at 37°C in a humidiﬁed
% CO2/air incubator.
reparation of LAK Normal Splenocytes
Spleen cells (1  106/mL) were plated in 225-cm2
issue culture ﬂasks (Costar, Cambridge, MA) con-
aining 6000 IU/mL recombinant interleukin (rIL)-2
Proleukin; Chiron BV, Amsterdam, The Nether- a
B&MTands) in culture medium of 4T1 supplemented with
-mercaptoethanol (5  105 mol/L) and sodium
yruvate (1 mmol/L; complete LAK medium). After 4
ays in a CO2 incubator at 37°C, cells were washed
nd tested for their ability to exert an antitumor re-
ponse in vivo.
ropagation of LAK SCID Cells
Single-cell suspensions of splenocytes and bone
arrow (BM) cells derived from SCID mice were
repared in complete LAK medium supplemented
ith 10 g/mL indomethacin (Sigma, St. Louis, MO).
ell suspensions at a concentration of 1  106/mL
ere plated in 6-well tissue culture plates (Corning,
ew York, NY) or tissue culture ﬂasks containing
000 IU/mL rIL-2, according to the total number of
ells obtained. Cell and rIL-2 concentrations were
djusted with fresh complete medium to 1  106/mL
nd 3000 IU/mL, respectively, every 3 to 4 days.
low Cytometry Analysis
Peripheral blood mononuclear cells (5  105)
ere stained directly with phycoerythrin anti-mouse
an NK cells (DX5) to detect NK1.1 cells, ﬂuores-
ein isothiocyanate (FITC) anti-mouse CD3 (17A2),
nd FITC anti-mouse CD8a (53-6.7). Phycoerythrin
at immunoglobulin M isotype standard (R4-22) and
ITC rat immunoglobulin G2b isotype standard
A95-1) were used as isotype controls. All reagents
ere purchased from BD PharMingen (San Diego,
A). All samples were preincubated for 10 min on ice
ith unlabeled rat anti-mouse CD32/16 antibodies
Southern Biotechnology Associates, Inc., Birming-
am, AL) to prevent nonspeciﬁc staining through the
c fraction of the labeled antibodies. Staining was
erformed as described previously [31].
T1 Clonogenic Assay
Lung metastases were measured as already de-
cribed [32]. Brieﬂy, lungs were harvested from 3 mice
f each experimental group 13 to 14 days after tumor
noculation. Single-cell suspensions were prepared in
erial dilutions in culture medium of 4T1 including 60
mol/L 2-amino-6 mercaptopurine (Sigma) and
lated in 100  20 mm tissue culture dishes (Becton
ickinson Labware, Franklin Lakes, NJ). Tumor col-
nies were ﬁxed and stained with 0.03% methylene
lue 10 to 14 days after plating. The number of tumor
olonies was calculated per mouse lung for each ex-
erimental group relative to 100% 4T1 colonies in the
ontrol group of untreated mice.
easurement of Cytotoxic Activity
Cells harvested from normal LAK and SCID-
AK cultures were washed, diluted to 5  106/mL,
nd tested in a standard 4-hour chromium 51 release
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4ssay, as previously described [33], against 5000 NK-
esistant (4T1) and NK-sensitive (Yac) target cells.
rradiation
Total body irradiation (TBI) was delivered by a
-MeV linear accelerator (Varian, Palo Alto, CA) at
ose rate of 1.9 Gy/min. Irradiation of single-cell
uspensions was performed by using a Gamma Cell
20 Excel Research irradiator (MDS Nordion, Ka-
ata, Ontario, Canada).
ell Therapy
F1 mice were conditioned with 4 Gy of TBI and
4 hours later were inoculated IV with 5  104 4T1
umor cells. On the following day, naive splenocytes
nd IL-2–activated splenocytes from normal or SCID
ice (20-30  106) were inoculated IV. In most ex-
eriments, rIL-2 was given intraperitoneally at 5 
04 IU/d in vivo for 3 to 4 days, starting from the day
f cell therapy. GVHD symptoms such as hunched
osture, rufﬂed fur and cachexia, and survival were
hecked daily. To distinguish GVHD from tumor
orbidity, each mouse was tested after death for the
resence of tumor metastases in the lungs and liver.
doptive Transfer Experiments and Measurement
f Tumor Growth
Lungs were removed from F1 mice, and cell sus-
ensions were inoculated into naive BALB hosts for
etection of residual tumor cells by an in vivo assay in
econdary recipients, as previously described [29].
rowth of intradermally inoculated tumors was mea-
ured once a week [29].
tatistical Analysis
Statistical signiﬁcance of tumor growth assessed
able 1. Effects of Syngeneic versus Allogeneic Cell Therapy on Surviva
Effector Cells
Survival,*
Median (Range) No. Mice
umor only 33 (20-137) 31
1 splenocytes 33 (22-205)‡ 26
ALB splenocytes 28 (25-50) 24
57 splenocytes 17 (13-20) 15
ALB LAK cells 33 (27-50) 18
BA LAK cells† 41 (28-180)‡ 18
1 LAK cells 38 (30-138)‡ 10
57 LAK cells 18 (14-20) 10
BALB/c  C57BL/6) F1 mice were inoculated with 5  104 4T1 c
20 to 25  106 effector cells derived from normal mice were give
3 consecutive days at 5  104 IU/d, starting from the day of ce
Survival in days.
Mice treated with DBA rIL-2-activated splenocytes (LAK) receive
Mice were killed without disease.y clonogenic assay was evaluated by the standard f
2-tailed unpaired Wilcoxon test. The Kaplan-Meier
ethod was used to calculate the probability of tu-
or-free survival as a function of the time after inoc-
lation of tumor challenge [34]. Statistical signiﬁcance
etween pairs of Kaplan-Meier curves was evaluated
y the Wilcoxon test of Breslow [35].
ESULTS
AK Cells of MiHC-Mismatched or
HC-Mismatched Splenocytes
Antitumor activity across minor histocompatibil-
ty complex (MiHC) or MHC antigen barriers was
ested in irradiated F1 mice inoculated with 4T1 tu-
or cells. TBI was given to allow temporal or perma-
ent engraftment of the allogeneic therapeutic cells.
iHC-mismatched LAK cells derived from DBA/2
ice resulted in a delay in tumor-related death, com-
ared with syngeneic BALB-LAK cells (the median
urvival was 41 and 33 days, respectively; Table 1).
he Kaplan-Meier probability of tumor-free survival
as signiﬁcantly higher after treatment with DBA-
AK cells than with BALB-LAK cells (P  .0014).
Treatment with MHC-mismatched parental C57
AK cells caused severe GVHD in F1 hosts, which
esulted in the death of 10 of 10 mice that died free of
umors earlier than mice treated with syngeneic F1
AK cells (median survival was 18 versus 38 days,
espectively; Table 1). However, the probability of
umor-free survival was signiﬁcantly higher after in-
culation with C57 LAK cells as compared with syn-
eneic F1 LAK cells (P .04) (data not shown). These
esults show that cell therapy with MiHC- or MHC-
ismatched activated splenocytes improves the prob-
bility of tumor-free survival; however, because T
ells contained in allogeneic LAK cells aggravate
VHD, an alternative cell source needs to be applied
mor-Inoculated Mice
Cause of Death No. Disease-
Free
SurvivorsTumor-Related GVHD-Related
31 0 0
25 0 1
24 0 0
0 15 0
18 0 0
14 2 2
9 0 1
0 10 0
hours after receiving 4 Gy of total body irradiation. One day later,
em intravenously, and rIL-2 was administered intraperitoneally for
py.
105 IU/d for 4 consecutive days.l of Tu
ells 24
n to th
ll thera
d 1.2 or safer induction of GVT effects.
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Allogeneic Killer Cells for Cancer
Bhe Effect of Gamma Irradiation on AlloCT
Naive or LAK C57 cells were irradiated in vitro
7.5 Gy) before injection into F1 mice that had been
noculated with 4T1 tumor cells 24 hours earlier. As
een in Table 2, both naive and LAK allogeneic ef-
ector cells given without in vitro irradiation induced
severe allogeneic reaction against the F1 hosts that
nally led to GVHD-related death of 17 of 17 mice in
ach experimental group after a median of 13 and 26
ays, respectively. However, in vitro irradiation of
ffector cells before inoculation into the mice totally
brogated the GVHD-related death of all hosts. Irra-
iation of naive or LAK cells signiﬁcantly prolonged
verall survival as compared with nonirradiated effec-
or cells (P  .0000 and P  .0004 for naive and LAK
ells, respectively). Also, irradiated LAK cells signiﬁ-
antly prolonged the median of survival over that of
ntreated controls (P .002). Killing activity directed
gainst tumor cells and NK-sensitive Yac cells, mea-
ured in vitro, was not affected by gamma irradiation,
ut all the recipients inoculated with irradiated effec-
or cells later died of tumor metastases (14/14 and
6/16) after a median survival of 34 and 39 days after
reatment with naive or LAK splenocytes, respectively
Table 2). These results show that although irradia-
ion of allogeneic effector cells used for immunother-
py prevented GVHD and did not abrogate antitumor
ffects in vitro, alloCT induced by the administration
f a single dose of irradiated donor lymphocytes was
ot sufﬁcient to provide a long-lasting GVT effect in
ivo.
henotypic Characterization of Effector Cells
pplied to Cell Therapy
Phenotypic analysis of naive splenocytes revealed
2% CD3, 3% DX5, and 4% CD3 DX5 cells.
fter rIL-2 activation in vitro, all 3 cell subsets in-
reased to levels of up to 45%, 20%, and 10%, re-
able 2. Effects of  Irradiation on Allogeneic Cell Therapy
Normal C57BL/6
Effector Cells
Irradiation of Effector
Cells In Vitro (7.5
Gy)
Survival*,
Median (Range) N
one 33 (17-49)
plenocytes  13 (9-20)
plenocytes  34 (22-105)
AK cells  26 (14-40)
AK cells  39 (30-97)
rradiated or nonirradiated naive splenocytes and rIL-2-activated
inoculation of 5  104 4T1 tumor cells into (BALB/c  C57B
previously.
D indicates not done.
Survival in days.
Killing activity against 4T1 (NK-resistant) or Yac (NK-sensitive) ta
mean  SE % cytotoxicity of 3 separate experiments in an effepectively (Table 3). In an attempt to achieve an an-
B&MTitumor effect by an enriched DX5 cell subset
ithout the CD3 cells responsible for GVHD, we
erformed a phenotypic analysis of spleen and BM
ells derived from 2 strains of SCID mice lacking the
-cell compartment of the immune system. BM cells
f C.B-17 and C57 SCID mice contain a small pro-
ortion of DX5 cells, whereas splenocytes derived
rom both strains contain 47% and 52% DX5 cells,
espectively (Table 4). To obtain sufﬁcient number of
ells for in vivo therapy experiments, cells were prop-
gated in vitro in the presence of IL-2 for 10 days,
esulting in 10-fold and 5-fold increments of lympho-
ytes derived from spleen cells and BM cells, respec-
ively (data not shown). Both displayed 60% to 78%
X5 cells and no CD3 or CD8 T cells or NK T
ells. An exception was the low percentage of DX5
ells derived from the BM of C.B-17 mice (35% after
0 days of culture). These results show that SCID
pleen or BM-derived cells can be propagated in vitro
nd can provide sufﬁcient numbers of DX5 cells,
ithout contamination of T cells, for application in a
herapeutic experimental model (Table 4).
e
Cause of Death
Killing Activity In
Vitro†
Tumor-Related GVHD-Related 4T1 Cells Yac Cells
37 0 ND ND
0 17 ND ND
14 0 ND ND
0 17 48  0.6 66  6
16 0 50  1 65  4
cytes (LAK) (30  106) were given intravenously 24 hours after
1 mice that had received 4 Gy of total body irradiation 24 hours
lls was determined by Chromium 51 release assay. Results represent
rget ratio of 100:1.
able 3. Phenotypic Analysis of Naive and LAK Splenocytes Derived
rom Normal C57BL/6 Mice
Cell Source
Cell-Surface Marker (% Positive Cells)
CD3 NK1.1 NK1.1 CD3
aive splenocytes 32  3.3* 3.3  0.9 3.6  3.1
AK cells† 45  10 20  1 10  3
henotypic analysis was performed by ﬂuorescence-activated cell-
sorter analysis.
Results represent mean  SE values of at least 3 separate samples.
Single-positive cells do not include double-positive DX5
CD3 cells.
LAK cells were prepared by activation of splenocytes in vitro witho. Mic
37
17
14
17
16
spleno
L/6) F
rget cerIL-2 for 4 days.
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4ntitumor Reactivity as Measured by Tumor
lonogenic Assay In Vitro
Antitumor activity was evaluated by tumor clono-
enic assay in vitro in lung cells derived from F1 mice
noculated with 4T1 tumor cells and treated with LAK
ells 13 days before lung harvest. The antitumor ac-
ivity of allogeneic LAK cells derived from MiHC-
ismatched DBA/2 mice or MHC-mismatched nor-
al and SCID C57 mice was compared with that of
yngeneic F1 or normal BALB and SCID C.B-17–
erived LAK cells. Cells isolated from the lungs of
umor-bearing untreated control mice contained 435
o 1015 tumor colonies in vitro, as determined in 5
eparate experiments. The percentage of tumor colo-
ies in cells isolated from the lungs of treated mice
elative to 100% tumor colonies in tumor-bearing
ontrol mice is presented in Figure 1. Allogeneic LAK
ells derived from MiHC-mismatched or MHC-mis-
atched normal and SCID mice were more efﬁcient
n preventing tumor growth (4%, 4%, and 1% tumor
olonies, respectively) than syngeneic LAK cells de-
ived from BALB, F1, and C.B-17 SCID mice (14%,
1%, and 37% tumor colonies, respectively). Com-
arison of the outcome of alloCT with that of synCT
evealed a nonsigniﬁcant advantage of using MiHC-
ismatched LAK (P  .08) and a signiﬁcant advan-
age of using normal MHC-mismatched LAK cells
P  .02) and SCID MHC-mismatched LAK cells
P  .03).
ffect of Allogeneic versus Syngeneic
CID-Derived LAK Cells on the Survival of
umor-Bearing Mice
F1 mice inoculated with 4T1 tumor cells were
reated 24 hours later with LAK cells derived from
pleen or BM cells of C57 SCID and C.B-17 SCID
ice. There was no apparent difference in the median
urvival of experimental groups treated with the vari-
us SCID effector cells (Table 5). However, com-
ared with alloCT with effector cells derived from
ormal mice (Table 1), C57 SCID–derived LAK cells
able 4. Fluorescence-Activated Cell-Sorter (FACS) Analysis of Spleen
CID Mice
Cell Source
Before Culture* (% Positive Cell
NK1.1 CD3 CD8 NK1.1 CD3
M C.B-17 3  1.0 2  1 0.2  0.2 0.4  0.4
pleen C.B-17 47  16 6.2  2.4 1.2  0.4 0.9  0.5
M C57BL SCID 5.5  1.0 1.3  1.3 0 1.4  1.4
pleen C57BL SCID 52  13 0.7  0.6 0.85  0.1 2.8  2.0
D indicates not done.
Naive spleen and bone marrow cells were derived from C.B-17 or
Results represent the mean  SE of at least 3 separate samples o
FACS analysis was performed on days 8 to 10 on cultures containid not cause GVHD; 0 of 18 and only 2 of 11 mice a
4reated with allogeneic C57 SCID-LAK spleen and
57 SCID-LAK BM cells, respectively, died of
VHD, whereas 15 of 15 and 10 of 10 mice treated
ith naive splenocytes or LAK cells derived from
ormal C57, respectively, died of GVHD (Table 1).
hese results (Table 5) show that allogeneic SCID–
erived LAK cells constitute a safe source of alloge-
eic effector cells for GVT induction without causing
VHD.
ffect of AlloCT versus synCT on Antitumor
ctivity In Vivo by Adoptive Transfer
xperiments
F1 mice inoculated with 4T1 tumor cells were
reated 24 hours later with naive or LAK cells derived
rom either normal allogeneic C57 and SCID mice or
yngeneic F1 and C.B-17 SCID mice. Fourteen days
igure 1. Tumor colony assay in vitro. The LAK splenocytes
erived from either normal (DBA/2, BALB/c, and C57BL/6) or
CID (C57 and C.B-17) mice were used as effector cells (20-25 
06) to treat (BALB/c  C57BL/6) F1 hosts inoculated with 4T1
umor cells. The number of tumor colonies in the lungs was deter-
ined on day 14 after tumor inoculation and calculated per mouse
ung for each experimental group relative to 100% 4T1 colonies in
he control group of untreated mice. There was a nonsigniﬁcant
dvantage for the comparison of DBA with BALB treatment (P 
08) but a signiﬁcant advantage for C57 over F1 treatment (P  .02)
ne Marrow (BM) Cells Derived from H-2d (C.B-17) and H-2b (C57)
After Culture‡ (% Positive Cells)
1 CD8 NK1.1 CD3 CD8 NK1.1 CD3 NK1.1 CD8
0 35  6.5 0.4  0.2 0.5  0.3 0.5  0.4 0
0 65  1 1.1  0.9 1.4  1.3 3.6  2.3 0
D 60  9 0.1  0.1 0 0.1  0.1 0  0
0 78  5 0  0 0  0 0.9  0.8 0  0
L/6 SCID mice.
and cultured cells.
-2 (3000 IU/mL).and Bo
s)†
NK1.
N
C57B
f naivend for C57 SCID over C.B-17 SCID (P  .03).
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Allogeneic Killer Cells for Cancer
Bfter tumor inoculation, lung cells were adoptively
ransferred intradermally into naive BALB mice. Se-
ial weekly measurements of tumor size are presented
n Figure 2, showing that lung cells derived from F1
ice treated with naive allogeneic C57 and LAK cells
r C57 SCID-LAK cells did not give rise to any tumor
olony growth in the adoptive recipients, whereas syn-
eneic F1 or C.B-17 SCID-LAK cells resulted in ex-
onential tumor growth similar to that observed in
ntreated tumor-bearing control mice. Follow-up of
urvival showed that most secondary hosts inoculated
ith lung cells derived from F1 mice treated with
aive allogeneic C57 and LAK cells or C57 SCID-
AK cells remained tumor-free for200 days (Figure
). Kaplan-Meier probability of tumor-free survival
mphasized the advantage of alloCT over synCT in
xerting antitumor effects (P  .0003 for C57 LAK
ells versus F1 LAK cells and P  .0001 for C57
CID-LAK cells versus C.B-17 SCID-LAK cells). All
able 5. The Effect of Syngeneic Versus Allogeneic SCID Splenocytes a
Effector Cells
Survival,*
Median (Range)
No.
Mice
umor only 33 (20-137) 31
.B-17 SCID-LAK spleen cells 33 (26-64) 22
.B-17 SCID-LAK BM cells 37 (23-201) 18
57 SCID-LAK spleen cells 39 (31-84) 18
57 SCID-LAK BM cells 41 (25-52) 11
BALB/c  C57BL/6) F1 mice were inoculated with 5  104 4T1 c
20 to 25  105 effector cells derived from SCID mice were giv
intraperitoneally for 3 consecutive days, starting from the day o
Survival in days.
igure 2. Tumor size measured in adoptive transfer recipients.
ung cells (1.5  106) from primary (BALB/c  C57BL/6) F1 mice
ere transferred intradermally into naive secondary BALB/c hosts
n day 14 after tumor inoculation. Primary F1 recipients received 4
y of total body irradiation 24 hours before inoculation of 5  104
T1 tumor cells and 20 to 25  106 splenocytes derived from
arious sources 1 day after tumor inoculation. Results represent 1 of
experiments. Experimental groups consisted of 5 to 9 mice in each
xperiment. m
B&MTffector cells that were allogeneic to the 4T1 tumor
ells were equally efﬁcient in the induction of antitu-
or effect (P  .05 for the comparison of naive C57
plenocytes versus C57 LAK cells and for normal C57
AK versus SCID C57 LAK cells).
ISCUSSION
LAK cells reacting against MiHC- or MHC-mis-
atched murine mammary carcinoma cells were
hown to exert GVT effects, thus improving the prob-
bility of tumor-free survival, as compared with no or
oor GVT effects induced by syngeneic effector cells.
owever, in most cases, such GVT effects were asso-
iated with an increased incidence of GVHD, as pre-
iously reported with naive splenocytes [29,36]. Be-
ause allogeneic naive lymphocytes and LAK cells
ontain both T and NK cells, we directed our efforts
oward investigating the GVT effects induced by ir-
Cells on the Survival of Mice Inoculated with 4T1 Tumor Cells
Cause of Death
No. Disease-Free
SurvivorsTumor-Related GVHD-Related
31 0 0
22 0 0
18 0 0
18 0 0
9 2 0
hours after receiving 4 Gy of total body irradiation. One day later,
hem intravenously. All mice received 5  104 IU of rIL-2 per day
herapy.
igure 3. Survival of secondary BALB/c recipients inoculated in-
radermally with 1.5  106 lung cells derived from primary (BALB/
x C57BL/6) F1 mice that were inoculated with tumor cells 14 days
reviously. Primary F1 recipients received 4 Gy of total irradiation
4 hours before tumor inoculation and 20–25  106 splenocytes
erived from various sources 1 day after tumor inoculation. Exper-
mental groups consisted of 10 to 12 mice pooled from 2 experi-nd BM
ells 24
en to t
f cell tents.
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4adiated LAK cells, in which radiosensitive T cells
annot exert GVHD, or we used a source of NK cells
lone in an attempt to prevent T cell–mediated
VHD. Indeed, irradiated LAK did not cause GVHD
ut were unable to mediate a long-lasting GVT effect.
he possible antitumor activity of NK cells in the
etting of HSCT independently of GVHD has been
uggested in several recent reports [17-20]. In our
tudy, cell sources enriched with NK cells syngeneic
r allogeneic to the tumor cells were evaluated as a
ossible source of safer cell therapy after HSCT. After
IL-2 activation and expansion in vitro, LAK cells
erived from C.B-17 and C57 SCID mice had no
D3 or CD8 cells and consisted mainly of DX5
ells, which exerted cytotoxic activity in vitro against
T1 tumor cells and NK-sensitive Yac cells, similarly
o LAK cells derived from normal splenocytes (data
ot shown).
As reported previously, SCID-derived cells given
o mice with and without MCA-38 tumor cells after
llogeneic HSCT did not induce GVHD in the re-
ipients [17,18]. Unlike previous reports in mice in-
culated with MCA-38 tumor, in our 4T1 tumor
odel, syngeneic and allogeneic SCID-LAK cells
ere compared and were administered after nonmy-
loablative TBI without HSCT. As evidenced by the
umor colony assay and adoptive transfer experiments,
K cells allogeneic to the tumor exerted efﬁcient
VT effects in tumor-bearing mice, in contrast to
K cells syngeneic to the tumor. Unfortunately,
robably because of a lack of memory NK cells, such
VT effects were short acting and thus not sufﬁcient
o exert a long-lasting in vivo effect. Because alloge-
eic NK cells, as well as irradiated LAK cells, includ-
ng radiosensitive T cells, did not cause GVHD, the
ossibility of exploiting their GVT capability over
onger periods of time through the use of multiple
oses given at short intervals should perhaps be con-
idered.
Taken together, our results support the use of
llogeneic cell–mediated immunotherapy based on the
se of T cell–depleted NK cells for the induction of
afe antitumor activity. NK cells have been shown to
ediate hybrid resistance, in which parental donor
ematopoietic cells, normal and malignant alike, may
e rejected by the F1 host even though T cells are
enetically tolerant to the allograft [37]. Our working
ypothesis predicts that similarly to the way that NK
ells can break tolerance to self in the course of hybrid
esistance, such cells might also serve as effector cells
or breaking tolerance to tumor cells. Furthermore,
IL-2–activated NK cells express on their surface the
umor necrosis factor–related apoptosis-inducing li-
and that mediates killing of many transformed cells
ut spares most normal somatic cells [38,39]. Various
ytokines known for their antitumor effects are also
ble to induce tumor necrosis factor–related apopto- a
6is-inducing ligand expression on activated NK cells,
hich suggests that through cytokine activation, anti-
umor effects might be enhanced via NK activation in
ivo by intrinsic factors or by exogenous rIL-2 or
ther cytokine administration [39]. NK activity is
ather complex and regulated via the inhibitory and
ctivating receptors [23,39,40]. Blockading their in-
ibitory receptor (KIR) molecules has been shown to
nhance antitumor activity directed against murine
eukemia [41]. However, because NK killing activity is
ediated through the “missing self” of a KIR-like
igand [22], allogeneic, intentionally mismatched
rather than matched) NK cells should be more effec-
ive in triggering the eradication of residual tumor
ells. As shown in our 4T1 model and as also indicated
n a recently reported clinical trial in patients with
cute myelogenous leukemia treated with haploiden-
ically mismatched stem cell allografts in an elegant
ork by Ruggieri et al. [19,20], allogeneic NK allo-
eactivity seems to have a therapeutic advantage in
revention of relapse when mismatching of NK allo-
eactivity exists in the direction of graft versus host.
imilarly, when NK alloreactivity is in the direction of
ost versus graft, the incidence of rejection is de-
reased, suggesting that alloreactive NK cells may also
e effective in eliminating residual hematopoietic cells
f host origin as conditioning for HSCT [19,20].
ecause allogeneic NK cells did not cause GVHD in
ur study or in other trials [17-20], activated alloge-
eic intentionally mismatched NK cells could be used
s tumor-selective killer cells against hematopoietic
umor cells and other tumor cells susceptible to NK
ell–mediated lysis.
LAK cells derived from normal BALB mice did
ot cause severe GVHD symptoms in F1 hosts, and
one of theses hosts died from GVHD. It is interest-
ng to note that although BALB and C57 mice were
qually matched with the mismatched F1 hosts, the
ntensity of GVHD induced by C57BL/6-derived
ells dramatically exceeded that induced by BALB-
erived cells. The intensity of GVHD and its lethal
onsequences are determined by the degree of MiHC
nd MHC mismatching, as well as by other genetic
actors, such as the cytokinetic potential of T cells, and
dditional factors that cannot be controlled intention-
lly. In our experimental models as in clinical practice,
he same degree of MiHC or MHC mismatching may
esult in uneventful transplantation in some individu-
ls and lethal GVHD in others. The fact that tumor-
yngeneic SCID-derived LAK cells did not exert an
ntitumor effect further emphasizes the major role of
ismatched NK alloreactivity in exerting an antitu-
or response.
In summary, these experiments, in accord with our
revious investigations and supported by indirect data
rom clinical studies, suggest a clear advantage of
lloCT over synCT in exerting GVT effects and em-
p
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Bhasize the potential use of intentionally mismatched
K cells, possibly in repeated doses, to achieve safe
nd effective immunotherapy of minimal residual dis-
ase. Clinical studies currently in progress are aiming
o further exploit the use of allogeneic cell–mediated
mmunotherapy, possibly in conjunction with HSCT,
or prevention or minimizing relapse, which continues
o be the single major barrier to successful HSCT.
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